Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression

Journal of Pathology

Volumn 224, Issue 1, 2011, Pages 10-21

  Bouwman, Peter ^a   Drost, Rinske ^a   Klijn, Christiaan ^a,b   Pieterse, Mark ^a   Gulden, Hanneke Van Der ^a   Song, Ji Ying ^a   Szuhai, Karoly ^c   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

embryo; homologous recombination; mouse model; p53; PALB2; tumour

Indexed keywords

NUCLEAR PROTEIN; PROTEIN P53; PROTEIN PALB2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GENOMIC INSTABILITY; GESTATION PERIOD; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INTERACTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; EMBRYO LOSS; EMBRYONIC DEVELOPMENT; FEMALE; GENE DELETION; GENES, P53; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HETEROZYGOTE; LYMPHOMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79953801997     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2861     Document Type: Article

References (44)

1. Xia B, Sheng Q, Nakanishi K, et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719-729.
2. Sy SM, Huen MS, Chen J,. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 2009; 106: 7155-7160.
3. Zhang F, Fan Q, Ren K, et al., PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009; 7: 1110-1118.
4. Zhang F, Ma J, Wu J, et al., PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009; 19: 524-529.
5. D'Andrea AD,. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010; 362: 1909-1919.
6. Reid S, Schindler D, Hanenberg H, et al., Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nature Genet 2007; 39: 162-164. (Pubitemid 46184345)
7. Xia B, Dorsman JC, Ameziane N, et al., Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nature Genet 2007; 39: 159-161. (Pubitemid 46184344)
8. Alter BP, Rosenberg PS, Brody LC,. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007; 44: 1-9. (Pubitemid 46142832)
9. Howlett NG, Taniguchi T, Olson S, et al., Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609. (Pubitemid 34815345)
10. Rahman N, Seal S, Thompson D, et al., PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet 2007; 39: 165-167. (Pubitemid 46184346)
11. Walsh T, King MC,. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103-105. (Pubitemid 46209856)
12. Jones S, Hruban RH, Kamiyama M, et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
13. Erkko H, Xia B, Nikkila J, et al., A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-319. (Pubitemid 46426155)
14. Tischkowitz M, Xia B, Sabbaghian N, et al., Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 2007; 104: 6788-6793. (Pubitemid 47175579)
15. King TA, Li W, Brogi E, et al., Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol 2007; 14: 2510-2518. (Pubitemid 47389559)
16. Skoulidis F, Cassidy LD, Pisupati V, et al., Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010; 18: 499-509.
17. Rodriguez CI, Buchholz F, Galloway J, et al., High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nature Genet 2000; 25: 139-140. (Pubitemid 30394979)
18. Jonkers J, Meuwissen R, van der Gulden H, et al., Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet 2001; 29: 418-425. (Pubitemid 34326692)
19. Bennett LM, McAllister KA, Blackshear PE, et al., BRCA2-null embryonic survival is prolonged on the BALB/c genetic background. Mol Carcinog 2000; 28: 174-183. (Pubitemid 30612997)
20. Ludwig T, Chapman DL, Papaioannou VE, et al., Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997; 11: 1226-1241. (Pubitemid 27235356)
21. Sharan SK, Morimatsu M, Albrecht U, et al., Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386: 804-810. (Pubitemid 27181248)
22. Suzuki A, de la Pompa JL, Hakem R, et al., Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997; 11: 1242-1252. (Pubitemid 27235357)
23. Hakem R, de la Pompa JL, Elia A, et al., Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genet 1997; 16: 298-302. (Pubitemid 27280216)
24. Donehower LA, Harvey M, Vogel H, et al., Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14: 16-22.
25. Szuhai K, Tanke HJ,. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nature Protoc 2006; 1: 264-275.
26. Klijn C, Holstege H, de Ridder J, et al., Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res 2008; 36: e13.
27. Venkatraman ES, Olshen AB,. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23: 657-663. (Pubitemid 46554715)
28. Sy SM, Huen MS, Chen J,. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem 2009; 284: 21127-21131.
29. Rantakari P, Nikkila J, Jokela H, et al., Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Hum Mol Genet 2010; 19: 3021-3029.
30. Hohenstein P, Kielman MF, Breukel C, et al., A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 2001; 20: 2544-2550. (Pubitemid 32531351)
31. Xu X, Qiao W, Linke SP, et al., Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genet 2001; 28: 266-271. (Pubitemid 32626030)
32. Greenblatt MS, Chappuis PO, Bond JP, et al., TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61: 4092-4097. (Pubitemid 32720976)
33. Holstege H, Joosse SA, van Oostrom CT, et al., High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009; 69: 3625-3633.
34. Lim DS, Hasty P,. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996; 16: 7133-7143. (Pubitemid 26389773)
35. Bachelier R, Xu X, Wang X, et al., Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene 2003; 22: 528-537. (Pubitemid 36188610)
36. Cheung AM, Hande MP, Jalali F, et al., Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res 2002; 62: 6194-6204. (Pubitemid 35244471)
37. Morales JC, Franco S, Murphy MM, et al., 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc Natl Acad Sci U S A 2006; 103: 3310-3315. (Pubitemid 43346466)
38. Ward IM, Difilippantonio S, Minn K, et al., 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 2005; 25: 10079-10086. (Pubitemid 41572753)
39. Marangoni E, Vincent-Salomon A, Auger N, et al., A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13: 3989-3998. (Pubitemid 47037607)
40. de Plater L, Lauge A, Guyader C, et al., Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2010; 103: 1192-1200.
41. Selzer RR, Richmond TA, Pofahl NJ, et al., Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005; 44: 305-319. (Pubitemid 41397100)
42. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121. (Pubitemid 32397092)
43. Tanke HJ, Wiegant J, van Gijlswijk RP, et al., New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling. Eur J Hum Genet 1999; 7: 2-11. (Pubitemid 29179026)
44. Luo G, Santoro IM, McDaniel LD, et al., Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nature Genet 2000; 26: 424-429.